@article{a1ee778a2ace4e569c8937f819fd424f,
title = "DNA methylation markers predict recurrence-free interval in triple-negative breast cancer",
abstract = "We lack tools to risk-stratify triple-negative breast cancer (TNBC). Our goal was to develop molecular tools to predict disease recurrence. Methylation array analysis was performed on 110 samples treated by locoregional therapy obtained from institutional cohorts. Discovered marker sets were then tested by Kaplan−Meier analyses in a prospectively collected TNBC cohort of 49 samples from the no-chemotherapy arms of IBCSG trials VIII and IX, and by logistic regression in a chemotherapy-treated cohort of 121 TNBCs from combined IBCSG trials and institutional repositories. High methylation was associated with shorter recurrence-free interval in the no-chemotherapy arm of the IBCSG studies, as well as in the chemotherapy-treated patients within the combined institutional and IBCSG chemotherapy cohorts (100 marker panel, p = 0.002; 30 marker panel, p = 0.05). Chromosome 19 sites were enriched among these loci. In conclusion, our hypermethylation signatures identify increased recurrence risk independent of whether patients receive chemotherapy.",
author = "Fackler, {Mary Jo} and Soonweng Cho and Leslie Cope and Edward Gabrielson and Kala Visvanathan and Kathleen Wilsbach and Danielle Meir-Levi and Lynch, {Charles F.} and Jeffrey Marks and Joseph Geradts and Regan, {Meredith M.} and Giuseppe Viale and Wolff, {Antonio C.} and Saraswati Sukumar and Umbricht, {Christopher B.}",
note = "Funding Information: We would like to thank F. Selk and D. Olson for providing study samples as well as everyone involved in curating the JH Integrated Breast Cancer Database. We thank the International Breast Cancer Study Group (IBCSG) and IBCSG trials VIII and IX participants and collaborators, and R. Kammler for coordination. This work was supported, in part, by an S.G. Komen Foundation IIR grant (KG110094) to C.B.U. and a Commonwealth Foundation grant to S.S. IBCSG trials VIII and IX were supported in part by the Swiss Group for Clinical Cancer Research, Cancer Research Switzerland, Oncosuisse, Cancer League Switzerland, Foundation for Clinical Cancer Research of Eastern Switzerland. Funding Information: S.S. has received research grants from the AVON Foundation and the Department of Defense, grants, licensing/royalty fees and consulting fees from Cepheid for QM-MSP and cMethDNA assays. M.J.F. has received licensing/royalty fees and consulting fees from Cepheid. No other authors have disclosed any conflicts of interest.",
year = "2020",
month = dec,
day = "1",
doi = "10.1038/s41523-020-0145-3",
language = "English (US)",
volume = "6",
journal = "npj Breast Cancer",
issn = "2374-4677",
publisher = "Nature Publishing Group",
number = "1",
}